| abstract |
The present invention relates to compounds of formula (I)n n n Formula In n n n n n n n Wheren n n R 1 is hydrogen or lower alkyl;n n n R 2 and R 2 ' are each independently hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;n n n X is O, S, or two hydrogen atoms that do not form a bridge;n n n A 1 and A 2 are each independently phenyl or a 6-membered heterocycle containing 1 or 2 nitrogen atoms;n n n B is a group of formula A or a 5-membered heterocyclic group of formula a, b, c or d:n n n Formula An n n n n n n n Formula an n n n n n n n Formula bn n n n n n n n Formula cn n n n n n n n Formula dn n n n n n n n [In the above formulas,n n n R 3 is lower alkyl, lower alkenyl, lower alkynyl, benzyl, lower alkyl-cycloalkyl, lower alkyl-cyano, lower alkyl-pyridinyl or lower alkyl-lower alkoxy-phenyl, or substituted or substituted with lower alkoxy Unsubstituted lower alkyl-phenyl, or phenyl unsubstituted or substituted with lower alkoxy, or lower alkyl-thienyl, cycloalkyl, lower alkyl-trifluoromethyl or lower alkyl-morpholinyl;n n n Y is -O-, -S- or a bond;n n n Z is -O- or -S-;n n n R 4 and R 5 are each hydrogen, lower alkyl, lower alkoxy, cyclohexyl, lower alkyl-cyclohexyl or trifluoromethyl, provided that at least one of R 4 and R 5 is hydrogen.n n n The compounds can be used as metabotropic glutamate receptor ligands in inhibiting or treating acute and / or chronic neurological disorders. |